Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Ensayo de fracción única versus múltiple de radioterapia ablativa estereotáctica para el tratamiento integral de oligometástasis/progresión

22 de septiembre de 2026 actualizado por: Robert Olson

Ensayo de no inferioridad de fracción única versus múltiple de radioterapia ablativa estereotáctica para el tratamiento integral de oligometástasis/progresión: SIMPLIFY-SABR-COMET

Stereotactic Ablative Radiotherapy (SABR) is a modern RT technique that delivers high doses of radiation to small tumor targets using highly conformal techniques, while trying to avoid healthy tissues and organs. However, SABR treatment requires increased planning, treatment time, cost and potential for higher toxicity due to the higher dose. The purpose of this study is to compare single fraction (SF) SABR vs. multiple fraction (MF) SABR in regards to toxicities, progression-free survival, quality of life (QoL), and cost-effectiveness. In a subset of patients, we will also compare patient QoL, hospitalization rates, and cost-effectiveness between patients who complete QoL questionnaires, record symptoms and receive healthcare provider-guided intervention vs. patients who complete QoL questionnaires only.

Descripción general del estudio

Descripción detallada

Radiation can be delivered in multiple fractions, or doses, and can take up to several weeks or months of treatment depending on the type of cancer. Radiation can also be offered in a single fraction. Both techniques have evidence for use in clinical care. Multiple fraction is offered to reduce the amount of radiation given at a single time that could reduce late toxicities. However, single fraction radiotherapy is more cost-effective and saves patient time. With this trial, we will compare single fraction vs. multiple fraction in regards to their impact on toxicity, progression-free survival: time from randomization to disease progression at any site or death, lesional control rate: lesion size post-SABR, quality of life and cost-effectiveness.

In a subset of sites, we will also investigate the impact of healthcare-provider guided intervention on quality of life. Questionnaires capture various symptoms such as pain, fatigue and information relating to physical, social, and mental wellbeing. This information can help shed light on patient experience and provide a better understanding of the effects of radiation therapy. In this trial, we will compare quality of life questionnaire completion, symptom reporting and healthcare-provider guided intervention vs. quality of life questionnaire completion alone, in regards to patient quality of life. Hospitalization rates and frequency of emergency department visits will also be investigated.

Sample size: The total sample size of 598 for this trial was calculated based on the primary endpoint of toxicity for the single vs. multiple fraction SABR randomization. Calculations were performed based on the results of the SABR-5 trial and our clinical judgement.

Quality Assurance: Radiation treatments are based on the current phase III SABR-COMET-3 trial and as per recent clinical evidence. All treatments will be planned as per protocol including computed tomography (CT) simulation, organs at risk contouring and undergo a quality assurance process.

For the subset of sites involved in the second randomization, training will be provided to patients on the use of Noona, a patient-reported outcome platform.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

598

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Robert Olson, MD, MSC, FRCPC
  • Número de teléfono: 250-645-7300
  • Correo electrónico: rolson2@bccancer.bc.ca

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

    • British Columbia
      • Kelowna, British Columbia, Canadá
        • Reclutamiento
        • BC Cancer
        • Contacto:
      • Prince George, British Columbia, Canadá, V2M 7E9
        • Reclutamiento
        • BC Cancer
        • Contacto:
        • Contacto:
        • Investigador principal:
          • Robert A Olson
      • Surrey, British Columbia, Canadá
        • Reclutamiento
        • BC Cancer
        • Contacto:
      • Vancouver, British Columbia, Canadá
        • Reclutamiento
        • BC Cancer
        • Contacto:
      • Victoria, British Columbia, Canadá
        • Aún no reclutando
        • BC Cancer - Victoria
        • Contacto:
    • Ontario
      • Greater Sudbury, Ontario, Canadá, P3E 5J1
        • Reclutamiento
        • Health Sciences North Research Institute
        • Investigador principal:
          • Andrew Pearce
        • Contacto:
          • Jessica Richer
          • Número de teléfono: 1922 705.522.6237
          • Correo electrónico: jricher@hsnri.ca
      • Toronto, Ontario, Canadá, M5G 1X6
        • Reclutamiento
        • Princess Margaret Cancer Centre | University Health Network
        • Investigador principal:
          • Chiaojung Jillian Tsai
        • Contacto:
          • Yoona Shin
          • Número de teléfono: 416-946-4558
          • Correo electrónico: yoona.shin@uhn.ca
    • Connacht
      • Galway, Connacht, Irlanda, H91 YR71
        • Reclutamiento
        • University Hospital Galway
        • Contacto:
        • Investigador principal:
          • Ronan McDermott
    • Dublin
      • Dublin, Dublin, Irlanda, D06 E1C9
        • Reclutamiento
        • St. Luke's Radiation Oncology Network
        • Contacto:
        • Investigador principal:
          • Lorna Keenan
    • Leinster
      • Dublin, Leinster, Irlanda, D18 AK68
        • Reclutamiento
        • Beacon Hospital
        • Contacto:
        • Investigador principal:
          • Alina Mihai
      • Dublin, Leinster, Irlanda, D07 WKW8
        • Reclutamiento
        • Mater Private Hospital
        • Contacto:
          • Lisa Scahill
          • Número de teléfono: +353 (1) 8034831
          • Correo electrónico: lscahill@mater.ie
        • Investigador principal:
          • Daniel Cagney
    • Munster
      • Cork, Munster, Irlanda, T12 DV56
        • Reclutamiento
        • Bon Secours Radiotherapy Cork in Partnership with UPMC Hillman Cancer Centre
        • Investigador principal:
          • Paul Kelly
        • Contacto:
          • Erica Bennett
          • Número de teléfono: +353 21-486-11
          • Correo electrónico: bennette10@upmc.ie
      • Cork, Munster, Irlanda, T12 DC4A
        • Reclutamiento
        • Cork University Hospital
        • Contacto:
        • Investigador principal:
          • Aisling Barry
      • Waterford, Munster, Irlanda, X91 DH9W
        • Reclutamiento
        • UPMC Whitfield Hospital - Waterford
        • Contacto:
        • Investigador principal:
          • Ciara Lyons

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • 1-5 current oligometastatic or oligo-progressive lesions

  • Age 18 years or older

  • Able to provide informed consent

  • Able to complete electronic entry of patient reported outcomes and questionnaires independently or with assistance from a caregiver/family/friend/research staff using electronic methods after providing consent to email use.

  • Life expectancy > 6 months

  • Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2

  • Controlled primary tumor: defined as at least 3 months since original tumor treated radically, with no progression at primary site (can be considered controlled if no evidence of the primary tumour on imaging [e.g. primary unknown])

  • A history including ECOG performance status, performed within 6 weeks prior to enrollment

  • Patient has had a CT chest, abdomen and pelvis or PET-CT within 10 weeks prior to enrollment, and within 13 weeks prior to treatment

  • Patient has had a nuclear bone scan (if no positron emission tomography-computed tomography [PET-CT]) within 10 weeks prior to enrollment, and within 13 weeks prior to treatment

  • Patient has had CT or MRI brain imaging if primary has a propensity for central nervous system metastases (if deemed appropriate by the treating investigator) within 10 weeks prior to enrollment, and within 13 weeks prior to treatment.

  • For patients with known spine metastases, patient has had MRI spine imaging within 10 weeks prior to enrollment, and with 13 weeks prior to treatment.

  • If solitary lung nodule for which biopsy is unsuccessful or not possible, patient has had an FDG (fluorodeoxyglucose) PET scan or CT (chest, abdomen, pelvis) and bone scan within 10 weeks prior to enrollment, and within 13 weeks prior to treatment

  • If colorectal primary with rising Carcinoembryonic antigen (CEA), but equivocal imaging, patient has had an FDG PET scan within 10 weeks prior to enrollment, and within 13 weeks prior to treatment

  • Patient is judged able to:

    • Maintain a stable position during therapy
    • Tolerate immobilization device(s) that may be required to deliver SABR safely
  • Negative pregnancy test for People of Child-Bearing Potential (POCBP) within 4 weeks of RT start date

Exclusion Criteria:

  • Uncontrolled concurrent malignant cancer

  • Lesion in femoral bone requiring surgical fixation

  • No chemotherapy agents (cytotoxic, or molecularly targeted agents) will be used within the period of time commencing 1 week prior to radiation, lasting until 1 week after the last fraction. See section 5.3.3 regarding this criterion.

  • Serious medical comorbidities precluding radiotherapy. These include interstitial lung disease in patients requiring thoracic radiation, Crohn's disease in patients where the gastrointestinal (GI) tract will receive radiotherapy, and connective tissue disorders such as lupus or scleroderma.

  • Substantial overlap with a previously treated radiation volume. Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints herein. For patients treated with radiation previously, similar biological effective dose calculations should be used to equate previous doses to the tolerance doses listed below. All such cases should be discussed with the local and study principal investigators (PIs).

  • Current malignant pleural effusion

  • Liver metastases located in the "Biliary no fly zone" defined for this trial as common biliary track, cystic duct and distal branches (1 cm) + 5 mm.

  • Inability to treat all sites of oligometastatic or oligoprogressive disease (all lesions must be suitable for both single- and multi-fraction SABR)

  • Presence of brain metastases as the sole site of disease

  • Maximum size of 5 cm for lesions outside the brain, except:

    • Bone metastases over 5 cm may be included, if in the opinion of the local PI it can be treated safely (e.g. rib, scapula, pelvis)
  • Any brain metastasis > 3.5 cm in size or a total volume of brain metastases greater than 30 cc is excluded

  • Clinical or radiologic evidence of spinal cord compression. Patients can be eligible if surgical resection has been performed

  • Patients with spine instability as judged by a Spinal Instability Neoplastic Score (SINS) of >12

  • Dominant brain metastasis requiring surgical decompression

  • Surgical resection of all metastases (i.e. no lesion available to be treated with SABR)

  • Complete response to systemic therapy, defined as the absence of visible disease on imaging

  • Pregnant or breast feeding

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación factorial
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Multiple fraction SABR (Arm 1)

Participants randomized to this arm will receive multiple fraction SABR

Participants randomized to this arm will receive MF SABR:

Dose/Fractionation are as follows:

Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory organ-at-risk (OAR) constraints are met: 48 Gy in 4 fractions (12 Gy/#), 54 Gy in 3 fractions (18 Gy/#), daily or every second day

Lung: Within 2 cm of mediastinum or brachial plexus 60 Gy in 8 fractions (7.5 Gy/#), 50 Gy in 5 fractions (10 Gy/#), daily

Bone: Any bone except spine: 35 Gy in 5 fractions (7 Gy/#), daily

Liver: 54 Gy in 3 fractions (18 Gy/#) or 5 fractions (10.8 Gy/#), daily or every second day

Spine: 24 Gy in 2 fractions (12 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily

Adrenal: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily

Lymph node/soft tissue: 40 Gy in 5 fractions (8 Gy/#) or 35 Gy in 5 fractions (7 Gy/#), daily

Brain - dose per institutional policy for stereotactic lesions (no whole brain RT).

Experimental: Single fraction SABR (Arm 2)

Participants randomized to this arm will receive single fraction SABR

Participants randomized to this arm will receive SF SABR

Treatment recommendations are as follows:

Lung: Greater than 2 cm from mediastinum or brachial plexus or if mandatory OAR constraints are met: 30 Gy in 1 fraction

Lung: Within 2 cm of mediastinum or brachial plexus 20 Gy in 1 fraction

Bone, Spine, Adrenal, lymph node/soft tissue: 20 Gy in 1 fraction

Liver: 30 Gy in 1 fraction

Brain: dose as per institutional policy

Comparador activo: Patient-reported outcome (PRO) collection : QoL reporting alone (Arm A)

Participants will complete the EuroQoL-5Dimensions-5levels (EQ-5D-5L) and Functional Assessment of Cancer Therapy-General (FACT-G) prior to each scheduled follow-up (FU).

Participants randomized to this arm will complete the EQ-5D-5L and FACT-G at baseline and each follow-up visit

Experimental: QoL reporting and healthcare provider (HCP) intervention guided by symptom screen (Arm B)
  • Patients complete EQ-5D-5L and FACT-G prior to each scheduled FU
  • Patient complete online adaptive symptom screen with HCP intervention, prior to each scheduled appointment

Participants randomized to this arm will complete the FACT,G, EQ-5D-5L, radiation-symptom screen and receive healthcare provider-guided intervention based on their symptom reports.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Adverse events
Periodo de tiempo: At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months

Occurrences and changes in grade 3 or higher adverse events related to treatment, according to CTCAE v5.0

At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
Change in patient-reported quality of life
Periodo de tiempo: At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months

As measured by the EQ-5D-5L. This questionnaire provides measures for mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. It also includes a numbered scale from 0 to 100 where 100 means the best health one can imagine, and 0 means the worst health one can imagine.

At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Lesional control rate
Periodo de tiempo: At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months

Rate is determined based on lesion size post-SABR using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1

At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
Progression-free survival
Periodo de tiempo: At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months

Time from randomization to disease progression at any site or death

At 6 weeks, 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months
Overall survival
Periodo de tiempo: Approximately at the end of year 5 of follow-up, at study completion

Time from randomization to death from any cause (exploratory)

Approximately at the end of year 5 of follow-up, at study completion
Resource utilization
Periodo de tiempo: At 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months

Assessed via patient- and provider-reported hospitalization rates, frequency of emergency department visits, number of patients with systemic or radiation therapy post SABR treatment on trial

At 3 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, 60 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Robert Olson, MD, MSc, FRCPC, BC Cancer - Prince George

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

16 de abril de 2025

Finalización primaria (Estimado)

30 de abril de 2035

Finalización del estudio (Estimado)

30 de mayo de 2035

Fechas de registro del estudio

Enviado por primera vez

28 de febrero de 2023

Primero enviado que cumplió con los criterios de control de calidad

23 de marzo de 2023

Publicado por primera vez (Actual)

24 de marzo de 2023

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

24 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • SIMPLIFY-SABR-COMET

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir